Brattström D, Bergqvist M, Larsson A, Holmertz J, Hesselius P, Rosenberg L, Brodin O, Wagenius G
Department of Oncology, Akademiska Hospital, University of Uppsala, Sweden.
Anticancer Res. 1998 Mar-Apr;18(2A):1123-7.
The formation of new microvessels from the existing vascular bed is known as angiogenesis and is normally under the tight regulatory control of angiogenic factors. This control is lost in malignant tumours. Previous studies have correlated increased microvessel density with poor prognosis in patients with primary lung cancer.
Our group measured levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in sera from 68 patients with non-small cell lung cancer (NSCLC) and compared elevated levels of VEGF and bFGF with clinical outcome. Serum basic FGF and VEGF were measured using commercially available enzyme- linked immunosorbent assays (R & D Systems Inc., Minneapolis, MN USA).
In 26/68 (38%) patients we found that elevated circulating levels of bFGF and in 27/68 (39%) serum samples levels of VEGF were elevated. Elevated bFGF values in sera was a statistically significant good prognostic factor, p- value = 0.048, when adjusted to stage and there was a trend in that patients with elevated levels of bFGF had a higher fraction of adenocarcinomas compared with squamous epithelial carcinomas (chi 2 = 2.0). No significant correlations could be demonstrated when elevated levels of VEGF in serum was present. Elevated levels of both VEGF and bFGF was present in 45% of the patients.
We found that elevated levels of bFGF is a good prognostic factor when measured in sera from NSCLC patients. As this result disagrees with earlier studies on other malignancies the results from our study needs to be further investigated in a prospective study.
从现有血管床形成新的微血管的过程称为血管生成，通常受到血管生成因子的严格调控。在恶性肿瘤中这种调控会丧失。先前的研究已将微血管密度增加与原发性肺癌患者的不良预后相关联。
我们小组检测了68例非小细胞肺癌（NSCLC）患者血清中的血管内皮生长因子（VEGF）和碱性成纤维细胞生长因子（bFGF）水平，并将VEGF和bFGF水平升高与临床结果进行了比较。血清碱性FGF和VEGF采用市售酶联免疫吸附测定法（美国明尼阿波利斯的R&D Systems公司）进行检测。
在26/68（38%）例患者中，我们发现循环中的bFGF水平升高，在27/68（39%）例血清样本中VEGF水平升高。血清中bFGF值升高是一个具有统计学意义的良好预后因素，校正分期后p值=0.048，并且存在一种趋势，即bFGF水平升高的患者腺癌的比例高于鳞状上皮癌（χ2 = 2.0）。当血清中VEGF水平升高时，未发现显著相关性。45%的患者同时存在VEGF和bFGF水平升高。
我们发现，在NSCLC患者血清中检测到bFGF水平升高是一个良好的预后因素。由于这一结果与先前关于其他恶性肿瘤的研究结果不一致，我们研究的结果需要在前瞻性研究中进一步调查。
